Minimum LTM EBITDA. Not permit the EBITDA of the Borrower and its Subsidiaries or Holdings and its Subsidiaries as the context may require after giving effect to the De-SPAC Transactions, as of the last day of any Test Period set forth in the table below, to be less than the amount set forth opposite such Test Period for such Test Period then ended: Test Period Ended Minimum LTM EBITDA December 31, 2020 ($12,792,000) March 31, 2021 ($11,766,000) June 30, 2021 ($7,717,000) September 30, 2021 $2,000,000 December 31, 2021 $9,500,000 March 31, 2022 $19,500,000 June 30, 2022 $29,000,000 September 30, 2022 $32,000,000 December 31, 2022 $32,000,000 March 31, 2023 $32,000,000 June 30, 2023 $32,000,000 September 30, 2023 $32,000,000 December 31, 2023 $32,000,000 March 31, 2024 $32,000,000 June 30, 2024 $32,000,000 September 30, 2024 $32,000,000 December 31, 2024 $32,000,000
Minimum LTM EBITDA. Permit EBITDA for the twelve consecutive month period ending as of the last day of any fiscal quarter listed in the table below to be less than: Fiscal Quarter Ending: EBITDA December 31, 2019 $0.0 March 31, 2020 $1,500,000 June 30, 2020 $3,000,000 September 30, 2020 $6,500,000 December 31, 2020 $10,000,000 March 31, 2021 $11,250,000 June 30, 2021 $12,500,000 September 30, 2021 $13,750,000 December 31, 2021 $15,000,000 March 31, 2022 $16,250,000 June 30, 2022 $17,500,000 September 30, 2022 $18,750,000 December 31, 2022 and thereafter $20,000,000
Minimum LTM EBITDA. Not permit the EBITDA of the Issuer and its Subsidiaries, as of the last day of any Test Period set forth in the table below, to be less than the amount set forth opposite such Test Period for such Test Period then ended: Test Period Ended Minimum LTM EBITDA March 31, 2022 $(36,000,000) June 30, 2022 $(44,000,000) September 30, 2022 $(40,000,000) December 31, 2022 $(37,000,000) March 31, 2023 $(23,000,000) June 30, 2023 $(23,000,0008,264,000) September 30, 2023 $(21,000,0005,015,000) December 31, 2023 $(16,000,000)5,030,000 March 31, 2024 $(16,000,000562,000) June 30, 2024 $(10,000,000896,000) September 30, 2024 $(5,000,000)495,000
Minimum LTM EBITDA. The Nutraceuticals Business shall have, at the end of each fiscal month set forth below, EBITDA as of the last day of such fiscal month for the 12 month period then ended of not less than the amount set forth below opposite such fiscal month: Fiscal Month Ending Minimum LTM EBITDA ------------------- ------------------ April 30, 2006 $ 4,150,000 May 31, 2006 $ 4,500,000 June 30, 2006 $ 4,800,000 July 31, 2006 $ 3,650,000 August 31, 2006 $ 3,100,000 September 30, 2006 $ 3,100,000 October 31, 2006 $ 4,350,000 November 30, 2006 $ 5,550,000 December 31, 2006 $ 6,900,000 January 30, 2007 $ 7,750,000 February 28, 2007 $ 8,350,000 March 31, 2007 $ 8,800,000 April 30, 2007 $ 8,850,000 May 31, 2007 $ 8,900,000 June 30, 2007 $ 9,050,000 July 31, 2007 $ 8,100,000 August 31, 2007 $ 8,650,000 September 30, 2007 $ 9,250,000 October 31, 2007 $ 9,300,000 November 30, 2007 $ 9,850,000 December 31, 2007 $ 10,500,000 January 30, 2008 $ 10,300,000 February 29, 2008 $ 10,900,000 March 31, 2008 $ 11,500,000
Minimum LTM EBITDA. Credit Parties on a consolidated basis shall have EBITDA (excluding non-cash charges and non-cash gains) for the 12-month period ended on the Closing Date of not less than Forty-Two Million Dollars ($42,000,000) after giving effect to the Related Transactions and based on the most recent available month-end financial statements or data;
Minimum LTM EBITDA. The Borrower will not permit EBITDA, for any period of twelve consecutive months ending on the last day of each month for the period beginning on September 30, 2016, through and including September 30, 2017, to be less than $3,750,000.00.
Minimum LTM EBITDA. Not permit the EBITDA of the Issuer and its Subsidiaries, as of the last day of any Test Period set forth in the table below, to be less than the amount set forth opposite such Test Period for such Test Period then ended: 60 (q) Pensions 61 (r) Centre of Main Interests and Establishment 61 Section 5. Registration of Underlying Shares 6165 5.1 Registration Statement 6166 5.2 Suspension Events 6367 5.3 Other Required Notices 6467 5.4 Effectiveness of Registration Statement 6467 5.5 Amendment to Registration Statement; Supplement of Prospectus 6468 5.6 Listing of Underlying Shares 6568 5.7 Registration of Underlying Shares 6568 5.8 Piggyback Registration Rights for Underwritten Offerings. 6568
Minimum LTM EBITDA. Measured for the fiscal quarter ending on the last day of each of the following months. QUARTER Minimum LTM EBITDA ($ in millions) March 2012 $26.7 June 2012 $28.4 September 2012 $25.6 December 2012 $25.4 March 2013 $25.3 June 2013 $25.2 September 2013 $25.1 December 2013 $24.8 March 2014 $24.7 June 2014 $24.6 September 2014 $24.5 December 2014 $24.2 March 2015 $24.2 June 2015 $24.0 September 2015 $23.9 Annex 2 Annex 3 Annex 4
Minimum LTM EBITDA. The Loan Parties shall maintain Consolidated EBITDA of the Company and its Subsidiaries of not less than the minimum amounts set forth below for the applicable periods, in each case calculated as of the end of each fiscal quarter for the twelve (12) calendar month-period then ending (without duplication): Fiscal Quarter Ending Minimum LTM EBITDA December 31, 2016 through June 30, 2017 $ 18,500,000 September 30, 2017 $ 23,000,000 December 31, 2017 $ 25,000,000 March 31, 2018 $ 29,000,000 June 30, 2018 $ 31,000,000
Minimum LTM EBITDA. (Section 8.2.14(i)). As of the Report Date, the Consolidated EBITDA of the Company and its Subsidiaries is [insert from Item 1(B)(xvi) above], which is greater than the minimum amounts set forth below for the applicable periods, in each case calculated as of the end of each fiscal quarter for the twelve (12) calendar month-period then ending (without duplication): Fiscal Quarter Ending Minimum LTM EBITDA December 31, 2016 through June 30, 2017 $ 18,500,000 September 30, 2017 $ 23,000,000 December 31, 2017 $ 25,000,000 March 31, 2018 $ 29,000,000 June 30, 2018 $ 31,000,000
